Chesapeake Urology Prostate Cancer Research Scholar Recipient Named for 2016
Through our ZERO Prostate Cancer Challenge event, Chesapeake Urology has worked diligently to raise funds to fully endow our permanent prostate cancer research scholarship through the American Urological Association’s Urology Care Foundation.
The scholarship endowment was fully funded to $1 million in 2015 and Chesapeake Urology is proud to announce that, after a rigorous peer review process, advanced prostate cancer researcher Mirja Rotinen, PhD, of Cedars Sinai Medical Center in Los Angeles, CA, is the 2016 recipient of the Chesapeake Urology Prostate Cancer Research Scholar Award.
“We are very excited to have identified such an outstanding candidate for this award,” says Dr. Sanford Siegel, “and we can only hope that one of these bright researchers will one day find the key to ending prostate cancer.”
With an estimated 220,800 cases expected to be diagnosed in 2016, prostate cancer is one of the most common cancers in the United States. And with 27,540 deaths expected this year, it remains the second leading cause of cancer death among men.
Dr. Rotinen’s two-year research award will begin on July 1, 2016 and her project titled, “Onecut2: A Novel Master Regulator Transcription Factor Predicted to be Highly Active in Castration-resistant Prostate Cancer,” focuses on the role of Onecut2, a protein coding gene, in prostate cancer metastasis, with the ultimate goal of providing new opportunities for tumor profiling and novel therapeutic options.